Global Lab Footprint The company operates across multiple regions with four fully owned harmonized laboratories in the US, Europe, Singapore, and China, underscoring a strong global reach that can support multinational clinical trials and cross-border data requirements.

Extensive Testing Portfolio Offers a broad suite of services from safety assessments and biomarker development to molecular testing, flow cytometry, pathology, and vaccine development support, enabling cross-functional collaboration with sponsors seeking integrated central laboratory solutions.

Experience and Reputation With over 25 years in the industry and recognition through awards, combined with high-quality globally harmonized data, the company can position itself as a reliable partner for long-term trials and complex studies.

Strategic Partnerships Past and ongoing collaborations, including ties with Eurofins CDMO Alphora and regional expansions in Shanghai, indicate a growth-focused strategy and capability to scale testing capacity in response to increasing client needs.

Growth and Scale Opportunity Revenue in the range of 100–250 million and a mid-sized employee base suggest potential for upscaling services for mid-market sponsors seeking high-quality central laboratory support, with opportunities to upsell adjacent services and longer study engagements.